Anthropic unveils Claude Sonnet 5 AI model focused on lower cost per token

Product / Tech
โดย Yahoo Finance·Read original
Summary · why it matters

Anthropic has revealed its newest AI model, Claude Sonnet 5, which is designed to be a less expensive version compared to its prior high-end model Opus 4.8. The model is part of the company's five series, which also includes the large Mythos 5 and the security-focused Fable 5, though those remain tied up with government regulation. Sonnet 5 aims to reduce cost per token, a unit of measurement in AI, as companies like Meta and Uber have pulled back on AI spending. The model is positioned for agentic use cases and is a general-purpose model rather than targeting specific professions. While improvements have been made to reduce errors, hallucination remains a lingering concern.

Impact on stocks 3

Artificial Intelligence▼ · 2 stocks
Meta Platforms Inc.
META
▼ NegativeDemandrelevance

Meta is cited as pulling back on AI spending, indicating reduced demand for AI models.

Robotics & Physical AI▼ · 1 stocks
Uber Technologies Inc
UBER
▼ NegativeDemandrelevance

Uber is cited as pulling back on AI spending, indicating reduced demand for AI models.

Theme Impact 2

Off-coverage companies 1

AnthropicPrivate▲ Positive
Technologyrelevance

Anthropic unveiled Claude Sonnet 5, a new AI model focused on lower cost per token.

Related news

Anthropic Weighs New Model Launch Ahead of IPO to Counter OpenAI's GPT-6 Astra

Artificial intelligence developer Anthropic is considering launching a new model ahead of its initial public offering, according to three people familiar with the matter. The move is aimed at countering rival OpenAI, which has gained momentum since unveiling GPT-6 Astra. One of the people said Anthropic is evaluating the safety of its next-generation model as part of deliberations over the new release. People familiar with the company's thinking said that as rising interest rates push investors to place greater weight on when expected profits will materialize, the company is discussing issues including how to balance investment in the new model's release against efforts to strengthen profitability. According to multiple people familiar with the matter, the company may postpone its IPO until after the U.S. midterm elections in November. Anthropic declined to comment.
Artificial Intelligence
ロイター·20mRead more →
2

OpenAI CEO Altman to Address AI Safety at UN Security Council Meeting

OpenAI CEO Sam Altman will speak about AI safety measures at a Security Council meeting next week, as world leaders gather in New York for the UN General Assembly. A company spokesperson confirmed the plan on the 18th, noting that the Security Council will hold a meeting on AI and international security on the 23rd. According to the spokesperson, Altman will discuss the need for international coordination and common safety standards, as well as the measures the company is taking. According to diplomatic sources, an Anthropic executive is also expected to attend the meeting, though this has not yet been finalized. Several AI industry executives have warned in recent weeks that AI could soon evolve autonomously and escape human control, and have called for a coordinated slowdown in development.
Artificial Intelligence
ロイター·1hRead more →
▲

UBS Flags AI Science Shift as Investment Theme After OpenAI Proof

UBS Wealth Management says artificial intelligence is moving beyond text generation into scientific research, opening investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industrial materials and utilities. The shift was highlighted by OpenAI's recent mathematical proof related to the Navier-Stokes equations, a centuries-old fluid dynamics problem and one of seven Millennium Prize Problems, which OpenAI tackled using 10,000 autonomous AI agents working in parallel for 88 hours before formalizing the proof with Lean, a system for machine-checked mathematical validation. In pharmaceuticals, multi-agent AI systems can simulate millions of protein variations in the cloud, and more than 170 AI-designed programs are already in development or clinical evaluation, including Phase III trials. In nuclear fusion, reinforcement-learning systems can predict plasma disruptions around 200 milliseconds before they occur and adjust magnetic coils thousands of times per second, while AI models in materials science can test millions of elemental combinations daily in search of properties for lighter, higher-density batteries, lower-heat computing hardware and potential room-temperature superconductors. The broader investment case centers on AI becoming a tool for automating scientific research rather than simply generating content, with companies exposed to AI infrastructure, pharmaceuticals, industrial materials and utilities positioned to benefit as these technologies move toward commercial applications.
GOOGLLYMSFTNVDAUBSG.SW
Biotech & Genomic Medicine ▲Artificial Intelligence ▲Fusion Energy ▲
Investing.com·3hRead more →
© 2026 MarketDXNews